The phase III IMbrave150 study evaluating Tecentriq in combination with Avastin in people with unresectable hepatocellular carcinoma met its co-primary endpoints of overall survival and progression-free survival, compared with standard-of-care sorafenib.
Wide Field Optical Coherence Tomography has the potential to significantly reduce the need for additional surgery after breast tumor resection, according to a study published in The Breast Journal.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute report a discovery that helps scientists understand why some tumors lack immune cell infiltration and are therefore unresponsive to newer PD-1 targeted therapies.
Researchers have found an antibody, imatinib, that eliminates chronic myeloid leukemia stem cells in mice and isolated human cancer cells and could keep one form of the disease from persisting after treatment.
A phase 3 clinical trial, CheckMate-9LA, evaluating Bristol-Myers Squibb's Opdivo (nivolumab) + low-dose Yervoy (ipilimumab), together with two cycles of chemo, for the first-line treatment of advanced non-small cell lung cancer met the primary endpoint of overall survival compared to chemo alone for up to four cycles followed by optional maintenance therapy.
The UCLA Jonsson Comprehensine Cancer Center has launched a CAR T-cell immunotherapy trial that will attack cancer cells by simultaneously recognizing two targets—CD19 and CD20—that are expressed on B-cell lymphoma and leukemia.
Novocure said the results from the STELLAR trial were published in The Lancet Oncology.
The International Association for the Study of Lung Cancer announced an open comment period for the “IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapy” paper.
Getting a reliable diagnosis of melanoma can be a significant challenge for pathologists. The diagnosis relies on a pathologist's visual assessment of biopsy material on microscopic slides, which can often be subjective.
Direct cost for metastatic breast cancer patients increases dramatically when their treatment differs from recommendations in the NCCN Clinical Practice Guidelines in Oncology.
